Adagene Inc. (ADAG)
NASDAQ: ADAG · Real-Time Price · USD
4.000
+0.280 (7.53%)
At close: May 27, 2026, 4:00 PM EDT
4.050
+0.050 (1.25%)
After-hours: May 27, 2026, 7:03 PM EDT
Adagene Revenue
In the year 2025, Adagene had annual revenue of $7.67M with 7,332.75% growth. Adagene had revenue of $7.67M in the half year ending December 31, 2025, with 840.35% growth.
Revenue (ttm)
$7.67M
Revenue Growth
+7,332.75%
P/S Ratio
34.54
Revenue / Employee
$59,929
Employees
128
Market Cap
264.29M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 7.67M | 7.57M | 7,332.75% |
| Dec 31, 2024 | 103.20K | -18.01M | -99.43% |
| Dec 31, 2023 | 18.11M | 8.82M | 94.90% |
| Dec 31, 2022 | 9.29M | -882.58K | -8.67% |
| Dec 31, 2021 | 10.18M | 9.47M | 1,351.72% |
| Dec 31, 2020 | 700.91K | 220.91K | 46.02% |
| Dec 31, 2019 | 480.00K | -1.03M | -68.24% |
| Dec 31, 2018 | 1.51M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Coherus Oncology | 46.88M |
| Orchestra BioMed Holdings | 32.72M |
| Foghorn Therapeutics | 28.22M |
| LENZ Therapeutics | 20.99M |
| Sol-Gel Technologies | 19.39M |
| Alector | 18.42M |
| Entrada Therapeutics | 5.74M |
| Camp4 Therapeutics | 3.93M |
ADAG News
- 8 days ago - Adagene Spotlights ADG126 Strategy as Masked CTLA-4 Trial Advances in Colorectal Cancer - MarketBeat
- 8 days ago - Adagene Transcript: Stifel 2026 Targeted Oncology Virtual Forum - Transcripts
- 8 days ago - Adagene Slides: Investor presentation - Filings
- 15 days ago - Adagene to Participate in Two Upcoming Investor Conferences - GlobeNewsWire
- 5 weeks ago - Adagene presents data from two Phase 1b/2 studies of muzastotug at AACR - TheFly
- 5 weeks ago - Adagene Presents Two Posters at AACR 2026 with New Data Highlighting Muzastotug's Potential as a Backbone Combination Therapy for Multiple Tumor Types - GlobeNewsWire
- 6 weeks ago - Adagene Adds Industry Veteran Peter Lebowitz to Scientific and Strategic Advisory Board - GlobeNewsWire
- 7 weeks ago - Adagene price target raised to $10 from $9 at Guggenheim - TheFly